Danaher (NYSE:DHR) Price Target Lowered to $285.00 at Citigroup

Danaher (NYSE:DHR) had its price objective trimmed by Citigroup from $305.00 to $285.00 in a research report released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the conglomerate’s stock.

DHR has been the topic of a number of other research reports. Evercore ISI lifted their price target on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Stephens reissued an “overweight” rating and set a $315.00 target price on shares of Danaher in a research report on Wednesday, October 23rd. Barclays dropped their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Royal Bank of Canada reduced their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Finally, Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a report on Thursday, October 31st. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Trading Down 0.5 %

Shares of DHR opened at $237.90 on Monday. Danaher has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The stock has a fifty day moving average of $236.08 and a two-hundred day moving average of $253.99. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a market capitalization of $171.83 billion, a PE ratio of 45.40, a price-to-earnings-growth ratio of 4.33 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the company earned $2.02 EPS. As a group, analysts forecast that Danaher will post 7.5 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is currently 20.61%.

Institutional Investors Weigh In On Danaher

A number of institutional investors have recently made changes to their positions in the company. Teachers Insurance & Annuity Association of America acquired a new position in Danaher in the third quarter worth $39,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Danaher in the 3rd quarter valued at about $40,000. FSA Wealth Management LLC acquired a new stake in Danaher during the third quarter worth about $50,000. Darwin Wealth Management LLC bought a new position in Danaher in the third quarter worth about $55,000. Finally, Modus Advisors LLC acquired a new position in Danaher in the fourth quarter valued at approximately $56,000. 79.05% of the stock is currently owned by institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.